Clinical trials: Prostate
Prostatic Cancer, Castration-Resistant
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Researchers in this study want to compare the effects of drug darolutamide and drug enzalutamide on physical function, including balance and daily activity, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- DaroAcT (NCT04157088)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bayer
Prostatic Hyperplasia
The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention
Acute urine retention, AUR, is often considered the most serious consequence of aging men with progressive benign prostatic hyperplasia (BPH). AUR is defined as the sudden and painful inability to void freely.
- Trial name
- NCT06319469
- Testing
- silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet, silodosin 8 mg capsule
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Beni-Suef University
Pancreatic Cancer, Metastatic Breast Cancer
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment.
- Conditions
- Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer
- Trial name
- NCT03073473
- Testing
- NantHealth GPS Cancer Test
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cota Inc.
Cancer
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral administration of eFT508.
- Trial name
- NCT02605083
- Testing
- eFT508
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Effector Therapeutics
PSA, Prostate Cancer
EDRN Prostate MRI Biomarker Study
The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated…
- Trial name
- P-MRI (NCT03784924)
- Testing
- MRI prostate
- Where
- United States
- Volunteers
- 950 people
- Sponsor
- University of Michigan
Prostate Cancer
Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients
This is a prospective phase II study of peri-operative docetaxel plus laparoscopic radical prostatectomy in patients with localized Gleason 7 pT2a-pT2b adenocarcinoma of the prostate and a risk of relapse after radical…
- Trial name
- NCT00127088
- Testing
- docetaxel, laparoscopic radical prostatectomy
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastasis
Pluvicto Real-world Investigation in Survival in Metastatic CRPC
This study aims to evaluate the various aspects of treatment effectiveness of [177Lu]Lu-PSMA-617 (Pluvicto) in mCRPC patients in both pre- and post-taxane settings.
- Trial name
- PRISM (NCT07697989)
- Volunteers
- 1,085 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Neoplasms, Genital Neoplasms, Male
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
The purpose of this study is to collect additional safety information on abiraterone acetate administered with prednisone to patients with metastatic castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
- Trial name
- NCT01217697
- Testing
- Abiraterone Acetate, Prednisone\Prednisolone
- Where
- 297 sites in United States, Australia and 22 more
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Prostate Cancer
Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients
The objective of this study is to evaluate the feasibility of two different chemotherapy protocols with adjusted doses for patients aged 75 and over who often have medical problems other than prostate cancer.
- Trial name
- GERICO10 (NCT01254513)
- Testing
- Docetaxel every 3 weeks + Prednisone, Docetaxel weekly+ Prednisone
- Where
- 31 sites in France
- Volunteers
- 66 people
- Sponsor
- UNICANCER
Castration-resistant Prostate Cancer, Metastatic Cancer
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
Open-label phase II multi-centre single arm study of Denosumab in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Cancer, Bone Metastases
- Trial name
- DICE (NCT03869762)
- Testing
- Xgeva, Xtandi
- Where
- 7 sites in Ireland
- Volunteers
- 7 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer, Prostate Cancer Metastatic
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
Researchers leading this study hope to learn about the safety of combining the study drug relugolix with another study drug called itraconazole or ritonavir in prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma
- Trial name
- NCT05679388
- Testing
- Relugolix Pill, Ritonavir, Itraconazole
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
Prostate Cancer
Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer
External beam radiotherapy (RT) is one of the standard curative treatment options for patients with prostate cancer (PC). Several randomised trials have shown excellent long-term biochemical outcome with higher radiation doses.
- Trial name
- Hypofraction (NCT01921803)
- Testing
- hypofractionation
- Where
- Belgium
- Volunteers
- 346 people
- Sponsor
- University Hospital, Ghent
Metastatic Castration-resistant Prostate Cancer
Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer
Taxotere is the current standard first-line chemotherapy for mCRPC and may be used as second-line therapy in good responders in first-line (Taxotere rechallenge).
- Trial name
- CABA-DOC (NCT02044354)
- Testing
- Taxotere, Jevtana
- Where
- France
- Volunteers
- 195 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of a peptide vaccine in treating patients with metastatic…
- Trial name
- NCT00616291
- Testing
- NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Baylor College of Medicine
Prostate Cancer
Prostate Conformal Cryotherapy
The goal of this clinical research study is to learn if using cryotherapy to treat only the part of the prostate that contains cancer is an effective treatment for prostate cancer.
- Trial name
- NCT00877682
- Testing
- Cryoablation
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
One of the biggest problems facing prostate cancer patients and their treating physicians is who needs to be treated and when. Common clinical and pathological parameters are useful (PSA, Gleason score, etc.) but do not clearly…
- Trial name
- NCT01350180
- Where
- 8 sites in Canada
- Sponsor
- Dr. Tamim Niazi
Prostate Cancer
Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases
In this Phase I study, patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases are treated with the cancer vaccine Bcl-xl_42-CAF09b.
- Trial name
- NCT03412786
- Testing
- Bcl-Xl_42-CAF09b vaccine
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Herlev Hospital
Prostate Cancer
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
This is a Phase II study to test the efficacy of exogenously administered GM-CSF in prostate cancer patients who have failed definitive local therapy, and have only serologic (PSA) evidence of progression.
- Trial name
- NCT00678054
- Testing
- GM-CSF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Lower Urinary Tract Symptoms
Herbal Supplement Prosta-OK® Neo as an Adjunct Therapy in Patients With Mild to Severe Non-neurogenic Male Lower Urinary Tract Symptoms Receiving Tamsulosin Therapy
The aim of the study is to uses Prosta-OK® Neo that contains herb extracts including lycopene, phellinus linteus, pomegranate, pumpkin seed, selenium and zinc that have been demonstrated with functions of inhibiting 5-alpha…
- Trial name
- NCT04418635
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Acrobio Healthcare Inc.
Prostate Cancer, High-risk Prostate Cancer
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
This is a single-arm, phase II study of neoadjuvant combination therapy of Androgen Deprivation Therapy (ADT), [Gonadotropin-Releasing Hormone (GnRH) agonist Leuprolide], androgen receptor (AR)-antagonist Darolutamide and…
- Trial name
- NCT07027124
- Testing
- Darolutamide, Pembrolizumab, Lupron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Icahn School of Medicine at Mount Sinai